Vasogen To Present at UBS Global Life Sciences Conference

Toronto, Ontario - September 21, 2004

Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today announced that its President and Chief Executive Officer, David Elsley, will present a Company overview at the UBS Global Life Sciences Conference at The Grand Hyatt New York at 10:30 a.m. on Tuesday, September 28, 2004 in New York City.

A live audio webcast of the presentation can be accessed through Vasogen's website at: www.vasogen.com. An archived replay will be available following the presentation.

Vasogen is a leader in the research and commercial development of immune modulation therapies targeting the chronic inflammation underlying cardiovascular disorders. Vasogen's lead product, Celacade™ (immune modulation therapy) is currently in pivotal phase III clinical trials for the treatment of chronic heart failure and peripheral arterial disease. The Company's 2,000-patient ACCLAIM trial, being conducted at cardiac centers throughout North America and Europe, is investigating the impact of Celacade™ on reducing the risk of mortality and morbidity in advanced chronic heart failure patients. Vasogen's 500-patient SIMPADICO trial, being conducted at medical centers throughout North America, is designed to further investigate the impact of Celacade™ on reducing the debilitating symptoms associated with peripheral arterial disease. Celacade™ is designed to target chronic inflammation by activating the immune system's physiological anti-inflammatory response to apoptotic cells. Vasogen is also developing a new class of drugs, designed to control inflammation in neurodegenerative disorders including Parkinson's and Alzheimer's disease.

---